PDZD4

Summary

PDZD4 (PDZ domain containing 4, HGNC:21167) is a protein-coding gene on chromosome Xq28, encoding PDZ domain-containing protein 4 (Q76G19).

Predicted to be located in cell cortex.

Source: NCBI Gene 57595 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 114 total — 1 pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001303512

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21167
Approved symbol	PDZD4
Name	PDZ domain containing 4
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1444, LU1, FLJ34125, PDZRN4L, LNX5
Ensembl gene	ENSG00000067840
Ensembl biotype	protein_coding
OMIM	300634
Entrez	57595

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 6 protein_coding, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000164640, ENST00000393758, ENST00000468491, ENST00000475140, ENST00000480418, ENST00000480650, ENST00000483693, ENST00000484792, ENST00000544474, ENST00000933007, ENST00000933008, ENST00000933009

RefSeq mRNA: 6 — MANE Select: NM_001303512 NM_001303512, NM_001303513, NM_001303514, NM_001303515, NM_001303516, NM_032512

CCDS: CCDS14732, CCDS78517, CCDS78518

Canonical transcript exons

ENST00000393758 — 8 exons

Exon	Start	End
ENSE00001952046	153802166	153804900
ENSE00003464827	153807279	153807369
ENSE00003477577	153805505	153805606
ENSE00003507047	153806742	153806840
ENSE00003680668	153805097	153805207
ENSE00003692386	153806071	153806133
ENSE00003734314	153808342	153808595
ENSE00003916725	153830239	153830544

Expression profiles

Bgee: expression breadth ubiquitous, 203 present calls, max score 99.46.

FANTOM5 (CAGE): breadth broad, TPM avg 8.9043 / max 373.9959, expressed in 662 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200914	7.6114	648
200910	0.4991	106
200912	0.4439	228
200913	0.1490	76
200911	0.1054	52
200909	0.0589	33
200908	0.0366	22

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	99.46	gold quality
cerebellar hemisphere	UBERON:0002245	99.41	gold quality
cerebellar cortex	UBERON:0002129	99.38	gold quality
right frontal lobe	UBERON:0002810	99.25	gold quality
anterior cingulate cortex	UBERON:0009835	98.96	gold quality
cortical plate	UBERON:0005343	98.87	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.78	gold quality
cerebellum	UBERON:0002037	98.77	gold quality
prefrontal cortex	UBERON:0000451	98.74	gold quality
amygdala	UBERON:0001876	98.49	gold quality
nucleus accumbens	UBERON:0001882	98.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.20	gold quality
frontal cortex	UBERON:0001870	97.94	gold quality
caudate nucleus	UBERON:0001873	97.92	gold quality
neocortex	UBERON:0001950	97.91	gold quality
putamen	UBERON:0001874	97.85	gold quality
embryo	UBERON:0000922	97.65	gold quality
ganglionic eminence	UBERON:0004023	97.65	gold quality
cerebral cortex	UBERON:0000956	97.15	gold quality
hypothalamus	UBERON:0001898	96.86	gold quality
forebrain	UBERON:0001890	96.66	gold quality
brain	UBERON:0000955	96.54	gold quality
granulocyte	CL:0000094	96.34	gold quality
Ammon’s horn	UBERON:0001954	96.31	gold quality
temporal lobe	UBERON:0001871	95.93	gold quality
right uterine tube	UBERON:0001302	95.85	gold quality
cerebellar vermis	UBERON:0004720	95.47	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.90	gold quality
superior frontal gyrus	UBERON:0002661	94.78	gold quality
adenohypophysis	UBERON:0002196	94.67	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

32 targeting PDZD4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-6728-3P	98.63	67.63	1534
HSA-MIR-31-5P	98.58	68.35	1239
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-1470	98.11	63.53	399
HSA-MIR-615-5P	98.10	63.76	591
HSA-MIR-5681A	97.99	67.17	1658
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-602	97.09	61.68	156
HSA-MIR-5192	96.89	63.35	879
HSA-MIR-339-5P	96.73	66.01	820

Literature-anchored findings (GeneRIF, showing 2)

• Might play an important role in the proliferation of SS cells and might be a suitable target for SS drugs. (PMID:15077175)
• PDZRN4L showed 49.9% total-amino-acid identity with PDZRN4 short isoform (PDZRN4S). PDZ, PR34H1 and PR34H2 domains were conserved between PDZRN4L and PDZRN4S. (PMID:15138636)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	PDZD4	ENSDARG00000090564
danio_rerio	PDZD4	ENSDARG00000098823
mus_musculus	Pdzd4	ENSMUSG00000002006
rattus_norvegicus	Pdzd4	ENSRNOG00000056174
drosophila_melanogaster	Slip1	FBGN0024728
caenorhabditis_elegans		WBGENE00016846

Paralogs (2): PDZRN3 (ENSG00000121440), PDZRN4 (ENSG00000165966)

Protein

Protein identifiers

PDZ domain-containing protein 4 — Q76G19 (reviewed: Q76G19)

Alternative names: PDZ domain-containing RING finger protein 4-like protein

All UniProt accessions (3): Q76G19, Q17RL8, V9GYN6

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm. Cell cortex.

Tissue specificity. Brain-specific. Expressed in fetal and adult brain. Up-regulated in synovial carcinomas.

Isoforms (2)

UniProt ID	Names	Canonical?
Q76G19-1	1	yes
Q76G19-2	2

RefSeq proteins (6): NP_001290441, NP_001290442, NP_001290443, NP_001290444, NP_001290445, NP_115901 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001478	PDZ	Domain
IPR036034	PDZ_sf	Homologous_superfamily
IPR051971	E3_ubiquitin-PDZ_ligase	Family

Pfam: PF00595

UniProt features (15 total): compositionally biased region 5, modified residue 2, region of interest 2, chain 1, domain 1, splice variant 1, sequence variant 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q76G19-F1	57.41	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 236, 454

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 53 (showing top): EFC_Q6, AGCTCCT_MIR28, RAAGNYNNCTTY_UNKNOWN, AHR_Q5, RFX1_01, CHENG_IMPRINTED_BY_ESTRADIOL, chrXq28, MTF1_Q4, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, SREBP_Q3, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, MIR8485, MIR1283, MIR6809_5P, MIR31_5P

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cell cortex (GO:0005938), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
cell periphery	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

826 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDZD4	BCAM	P50895	749
PDZD4	CNTN6	Q9UQ52	549
PDZD4	MCAM	P43121	548
PDZD4	LAMA5	O15230	547
PDZD4	LIPN	Q5VXI9	528
PDZD4	FUT2	Q10981	497
PDZD4	CFTR	P13569	455
PDZD4	LNX2	Q8N448	447
PDZD4	HSFX1	Q9UBD0	447
PDZD4	IDH3G	P51553	444
PDZD4	TGM1	P22735	435
PDZD4	KEL	P23276	428
PDZD4	NHERF4	Q86UT5	418
PDZD4	RASSF7	Q02833	416
PDZD4	MARVELD1	Q9BSK0	414

IntAct

31 interactions, top by confidence:

A	B	Type	Score
MAP2K2	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
KIR3DL3	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
ABCC4	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF16	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
ASIC3	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
PDZD4	ATP2B4	psi-mi:“MI:0407”(direct interaction)	0.440
CYSLTR2	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
DGKK	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
DGKZ	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
DOCK4	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
FRMPD4	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
FZD7	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
TAMALIN	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
PDZD4	E6	psi-mi:“MI:0407”(direct interaction)	0.440
E6	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
ORF putative E6	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
KCNA5	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
PBK	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
RALBP1	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
RASSF6	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
SLC15A5	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
SLCO1C1	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
TJP2	PDZD4	psi-mi:“MI:0407”(direct interaction)	0.440
PDZD4	APIP	psi-mi:“MI:0915”(physical association)	0.370
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
NDEL1	PDZD4	psi-mi:“MI:0915”(physical association)	0.000
mutL	PDZD4	psi-mi:“MI:0915”(physical association)	0.000
GFI1B	PDZD4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): PDZD4 (Two-hybrid), PDZD4 (Reconstituted Complex), CEP76 (Two-hybrid), KCTD9 (Two-hybrid), ENKD1 (Two-hybrid), TRAF2 (Two-hybrid), TRAF3 (Two-hybrid), MTUS2 (Two-hybrid), DNMT3L (Two-hybrid), CTDSP1 (Two-hybrid), IKZF3 (Two-hybrid), DYDC1 (Two-hybrid), ASCL4 (Two-hybrid), JRK (Two-hybrid), PDZD4 (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2JUG7, A1L390, E9Q0S6, O08774, O14924, O15085, O43182, O54834, O54960, O60307, O75052, P57095, Q13009, Q3U1V8, Q3U214, Q3UHC7, Q4VAC9, Q5DU25, Q5JU85, Q5RBI7, Q5SXA9, Q5VWQ8, Q60610, Q64512, Q6AX33, Q6DN90, Q6NXJ0, Q6P0Q8, Q6P1I6, Q6ZMN7, Q76G19, Q76LL6, Q76M68, Q7T2V3, Q810W7, Q8CGE9, Q8IX03, Q8R0S2, Q8R4H2, Q8WYP3

Diamond homologs: A0A1L8FG46, A0A8C0TYJ0, D3YY23, E7FDW2, F1MAD2, G2Q0E2, O14907, O14910, O35274, O35867, O55164, O60106, O88951, O88952, P31007, P57105, P68907, Q00940, Q05568, Q09506, Q0P5E6, Q0P5F3, Q0V8R5, Q12959, Q13424, Q13425, Q13884, Q1L5Z9, Q22638, Q28626, Q2KHN1, Q2KIB6, Q2TBT8, Q32LM6, Q3T0C9, Q5F425, Q5FWL3, Q5PYH6, Q5R7T5, Q5RAA5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	79
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
564868	GRCh37/hg19 Xq21.31-28(chrX:91140025-155233731)x1	Pathogenic

SpliceAI

1559 predictions. Top by Δscore:

Variant	Effect	Δscore
X:153804896:CCGGG:C	acceptor_gain	1.0000
X:153804897:CGGG:C	acceptor_gain	1.0000
X:153804897:CGGGC:C	acceptor_gain	1.0000
X:153804898:GGG:G	acceptor_gain	1.0000
X:153804899:GG:G	acceptor_gain	1.0000
X:153804900:GCTA:G	acceptor_loss	1.0000
X:153804901:C:CC	acceptor_gain	1.0000
X:153804907:C:CT	acceptor_gain	1.0000
X:153804908:A:T	acceptor_gain	1.0000
X:153805092:CTCA:C	donor_loss	1.0000
X:153805093:TCA:T	donor_loss	1.0000
X:153805094:CACCT:C	donor_loss	1.0000
X:153805096:C:CG	donor_loss	1.0000
X:153805204:CCAG:C	acceptor_gain	1.0000
X:153805205:CAG:C	acceptor_gain	1.0000
X:153805205:CAGC:C	acceptor_gain	1.0000
X:153805208:C:CC	acceptor_gain	1.0000
X:153805500:CACA:C	donor_gain	1.0000
X:153805501:ACAC:A	donor_loss	1.0000
X:153805503:A:AC	donor_gain	1.0000
X:153805504:C:CC	donor_gain	1.0000
X:153805504:CCTGA:C	donor_gain	1.0000
X:153805551:T:TA	donor_gain	1.0000
X:153805602:TTAAT:T	acceptor_gain	1.0000
X:153805603:TAAT:T	acceptor_gain	1.0000
X:153805604:AAT:A	acceptor_gain	1.0000
X:153805605:AT:A	acceptor_gain	1.0000
X:153805607:C:CC	acceptor_gain	1.0000
X:153805613:C:CT	acceptor_gain	1.0000
X:153805614:A:T	acceptor_gain	1.0000

AlphaMissense

5074 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:153803621:C:G	R681P	1.000
X:153803637:A:G	W676R	1.000
X:153803637:A:T	W676R	1.000
X:153803645:C:A	G673V	1.000
X:153803645:C:T	G673D	1.000
X:153803646:C:G	G673R	1.000
X:153803650:C:A	K671N	1.000
X:153803650:C:G	K671N	1.000
X:153803659:G:C	S668R	1.000
X:153803659:G:T	S668R	1.000
X:153803661:T:G	S668R	1.000
X:153803673:C:G	D664H	1.000
X:153803694:G:T	R657S	1.000
X:153803705:A:C	I653S	1.000
X:153803705:A:G	I653T	1.000
X:153803705:A:T	I653N	1.000
X:153803715:C:G	A650P	1.000
X:153803717:C:G	R649P	1.000
X:153803718:G:T	R649S	1.000
X:153803726:A:G	L646P	1.000
X:153803749:C:A	K638N	1.000
X:153803749:C:G	K638N	1.000
X:153803760:A:C	Y635D	1.000
X:153803760:A:G	Y635H	1.000
X:153803768:C:A	G632V	1.000
X:153803768:C:T	G632E	1.000
X:153803782:C:A	K627N	1.000
X:153803782:C:G	K627N	1.000
X:153803784:T:C	K627E	1.000
X:153803791:C:A	W624C	1.000

dbSNP variants (sampled 300 via entrez): RS1000424478 (X:153806194 C>A,T), RS1000643431 (X:153814331 G>A), RS1000796004 (X:153832469 C>G,T), RS1000912027 (X:153832054 G>C), RS1001228823 (X:153822590 C>T), RS1001574116 (X:153826972 C>T), RS1001611843 (X:153802251 G>A), RS1001899833 (X:153818857 G>A), RS1002210109 (X:153803865 G>T), RS1002499614 (X:153820663 C>T), RS1002505147 (X:153804135 C>T), RS1002750563 (X:153821171 C>T), RS1002988887 (X:153808190 G>A), RS1003063808 (X:153807891 G>A,T), RS1003132992 (X:153825304 C>T)

Disease associations

OMIM: gene MIM:300634 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (4): intellectual disability (MONDO:0001071), microcephaly (MONDO:0001149), movement disorder (MONDO:0005395), autism (MONDO:0005260)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D009069	Movement Disorders	C10.228.662

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects splicing, decreases expression	2
Valproic Acid	affects expression, increases methylation	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
butyraldehyde	increases expression	1
aflatoxin B2	decreases methylation	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Aldehydes	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	decreases expression	1

Clinical trials (associated diseases)

296 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT01662414	PHASE4	COMPLETED	Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson’s Disease
NCT04871464	PHASE4	UNKNOWN	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson’s Disease
NCT06710574	PHASE4	RECRUITING	Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson’s Disease
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT01838278	PHASE3	UNKNOWN	Effectiveness of Vojta Therapy in Motor Development of Preterm Children
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00001929	PHASE2	COMPLETED	Treatment of Parkinson’s Disease With Eliprodil
NCT00331669	PHASE2	UNKNOWN	Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
NCT00406029	PHASE2	COMPLETED	Dyskinesia in Parkinson’s Disease (Study P04501)
NCT00537017	PHASE2	COMPLETED	Follow Up Safety Study of SCH 420814 in Subjects With Parkinson’s Disease (P05175)
NCT00693472	PHASE2	TERMINATED	Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
NCT01385592	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
NCT01491529	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
NCT01491932	PHASE2	COMPLETED	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
NCT02500628	PHASE2	COMPLETED	Heart Rate Variability in Response to Metformin Challenge
NCT04536987	PHASE2	COMPLETED	Robot Therapy for Rehabilitation of Hand Movement After Stroke
NCT04912115	PHASE2	SUSPENDED	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
NCT05636852	PHASE2	TERMINATED	Altropane Dose for Imaging Patients With Suspected Parkinson’s Disease
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00001663	PHASE1	COMPLETED	Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation
NCT02589340	PHASE1	TERMINATED	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
NCT03065192	PHASE1	COMPLETED	Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson’s Disease
NCT07232147	PHASE1	NOT_YET_RECRUITING	Clinical Research on Stem Cell Therapy for Parkinson’s Disease
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills